Diffuse Midline Glioma, H3 K27M-Mutant Clinical Trials

28 clinical trials for Diffuse Midline Glioma, H3 K27M-Mutant across international registries, including 16 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 — RECRUITING · PHASE3
• CAR T Cells to Target GD2 for DMG — RECRUITING · PHASE1
• Atovaquone Combined With Radiation in Children With Malignant Brain Tumors — RECRUITING · PHASE1
• Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Trial — RECRUITING · PHASE2
• Combination Therapy for the Treatment of Diffuse Midline Gliomas — RECRUITING · PHASE2
• Study of Olutasidenib and Temozolomide in HGG — RECRUITING · PHASE2
• Targeted Pediatric High-Grade Glioma Therapy — RECRUITING
• Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant — RECRUITING · PHASE2
• A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma — RECRUITING · PHASE2
• rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG — RECRUITING · PHASE1
• FUS Etoposide for DMG — RECRUITING · PHASE1
• Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms — RECRUITING · PHASE1
• Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification — RECRUITING
• International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository — RECRUITING
• CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults — RECRUITING · PHASE1
• International cooperative Phase III trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents < 18 years. — RECRUITING
• Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma — TERMINATED · PHASE1
• Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status) — SUSPENDED · PHASE1
• Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) — NOT_YET_RECRUITING · PHASE1
• A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors — NOT_YET_RECRUITING · PHASE1
• Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG) — TERMINATED · PHASE1
• H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas — COMPLETED · PHASE1
• Oral AMXT 1501 Dicaprate in Combination With IV DFMO — TERMINATED · PHASE1
• A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG) — TERMINATED · PHASE1
• Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered — TERMINATED
• Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas — COMPLETED · PHASE1
• RE-irradiation of Diffuse MIdline Glioma paTients — NOT_YET_RECRUITING · NA

Refine this search